U.S. FDA approves Gilead’s Covid-19 drug remdesivir for young children – CNBC
A sign is posted in front of the Gilead Sciences headquarters on April 29, 2020 in Foster City, California.
Justin Sullivan | Getty Images
The U.S. Food and Drug Administration on Monday granted approval for Gilead’s Covid-19 drug remdesivir to treat infants and children over 28 days of age.
The FDA’s decision makes the drug the first approved Covid-19 treatment for children less than 12 years of age, the agency said.
